 Home > Active Ingredient News > Diagnostic Test > Roche discontinues Phase III clinical study of antisense RNA therapy tominersen

Roche discontinues Phase III clinical study of antisense RNA therapy tominersen

 Last Update: 2021-05-03
 Source: Internet
 Author: User

Tags

dickson data logger

haloperidol 1 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compileriver

In response to Huntington's disease, Roche signed a patent license agreement with Ionis as early as 2017 for a new antisense therapy for proteins related to Huntington's disease.

Roche said that after the independent data committee "recommended the potential benefits and risk status of study participants based on investigating therapies," the company has stopped the administration of the third phase clinical study of the antisense drug tominersen for huntingtin and mutants.

Roche obtained the license of tominersen (formerly IONIS-HTTRx) in 2017, and paid Ionis Pharmaceuticals a US$45 million license fee.

Roche also stopped an open-label extension study called GEN-EXTEND, which used the same high-dose and low-dose protocol.

Roche pointed out that the committee's decision did not involve new security risks.

Tominersen is an anti-nucleic acid drug that binds to Huntington mRNA and degrades this mRNA through the RNA degradation system, thus reducing the expression of toxic proteins, which may change the course of the disease.

Reference source:

2.
Roche Suspends Early-Stage Huntington's Disease Trial After Catheter-related Infections

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Sodium diatrizoate hydrate 99.00% White powder AsiaChem

CAS No.: 737-31-5

Pharmacy Grade

$442-450/KG FOB

3,5-Diacetamido-2,4,6-triiodobenzoic acid 99% 50978-11-5 white powder silworld

CAS No.: 50978-11-5

$500-520/KG FOB

Barium Sulphate

CAS No.: 13462-86-7

Industrial Grade

$3/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.